|
|
Special Interview With Julian Adams, Developer Of Velcade
Julian Adams discusses the development of Velcade and his current work on groundbreaking approaches to the treatment of myeloma
|
|
Update On The Velcade APEX Trial For Relapsed Myeloma
Update On Neuropathy In Patients On The Velcade APEX Trial
Frontline Therapy With Velcade
Combination Therapy With Melphalan and Velcade
Melphalan, prednisone, and Velcade In Previously Untreated Elderly Patients
Combination Therapy With Velcade, Adriamycin and Dexamethason (PAD)
Prophylaxis For Herpes Zoster (Shingles) With Velcade Therapy
Combination Therapy With Melphalan, Prednisone and Revlimid
Combination Therapy With Thalidomide And Dexamethasone In Elderly Patients
Combination Therapy With Melphalan, Prednisone and Thalidomide
Combination Therapy With Melphalan, Prednisone and Thalidomide
Gene Expression In Patients Treated With Thal/Dex
Combination Therapy With Thalidomide, Velcade And Dexamethasone
Therapy With Velcade And The Radiopharmaceutical Quadramet
Combination Therapy With Revlimid and Velcade
Aplidin For Relapsed/Refractory Myeloma
Phase I Trial Of Atipromod
Stem Cell Mobilization With AMD-3100
Stem Cell Harvesting Using GCSF Alone
Overview Of The IMF's Bank On A Cure Program
SNP Analysis of Myeloma Transplant Patients
Myeloma In Younger Patients
Genetic Abnormalities of Patients Diagnosed With MGUS or Smoldering Myeloma
Effect Of Velcade Therapy On Markers Of Immune Function
Effect Of Velcade Therapy On Markers Of Bone Resorption
Use Of The Free Lite Chain (FLC) Assay
Velcade (Bortezamib)
|
|
|
Dr. Paul Richardson of the Dana Farber Cancer Institute provides an update on the Velcade APEX trial |
|
|
|
|
Dr. San Miguel presented data on the rate of peripheral neuropathy in the APEX Velcade trial |
|
|
|
|
Dr. Jagannath’s reports on a multi-center trial for newly diagnosed myeloma patients receiving frontline therapy with Velcade |
|
|
|
|
Dr. Cavenagh presented results of a trial combining Velcade with another chemotherapy agent, melphalan, in patients with relapsed/refractory disease |
|
|
|
|
|
Dr. San Miguel presented interim data on the ongoing PETHEMA study of melphalan, prednisone, and Velcade in elderly, previously untreated myeloma patients |
|
|
|
|
|
Dr. Cavenagh reported on his ongoing trial combining Velcade, Adriamycin, and dexamethasone (PAD) in previously untreated myeloma |
|
|
|
|
Dr. Vij addressed the increased incidence of herpes zoster (shingles) with Velcade in the peri-transplant setting and preventative measures that can be taken to avoid this complication |
|
Revlimid (Lenalidomide)
|
|
|
Dr. Palumbo reported on the results of a Phase II trial of melphalan/prednisone/revlimid |
|
Thalomid (Thalidomide)
|
|
|
Dr. Ludwig presented an interim analysis of an ongoing trial of thal/dex versus MP in 205 elderly (median age 72), newly diagnosed patients with myeloma |
|
|
|
|
Dr. Facon reports on an interim analysis of the ongoing Intergroup Francais du Myelome (IFN) 99-06 clinical trial comparing melphalan–prednisone (MP), melphalan-prednisone-thalidomide (MPT), and stem cell transplant with reduced-dose-chemotherapy (melphalan 100 mg/m2 or “mel 100”) in elderly (65-75 years of age), newly diagnosed myeloma patients |
|
|
|
|
|
Dr. Palumbo began presents results a trial of melphalan/prednisone/thalidomide (MPT)for myeloma patients over 65 years if age |
|
|
|
|
Dr. Kumar presented the results of a gene expression study conducted on patients who were randomized to receive either thalidomide and dexamethasone |
|
Novel Agent Combinations
|
|
|
Dr. Wang presented interim results of a study of combination therapy with Thalidomide, Velcade and Dexamethasone in newly-diagnosed myeloma patients |
|
|
|
|
Dr. Dispenzieri presented data on a pre-clinical mouse study with the combination of Velcade and the radiopharmaceutical Quadramet (153 samarium EDTMP) |
|
|
|
|
|
Dr. Richardson also presented early data on the Phase I Revlimid + Velcade trial for relapsed and refractory myeloma |
|
New Agents
|
|
|
|
Dr. San Miguel presented preliminary data from a Phase I/II study in patients with relapsed/refractory myeloma of the novel therapy Aplidin, which is a marine-derived molecule with a novel mechanism of action |
|
|
|
|
|
Dr. Wang presented data on a Phase I dose escalation multi-center clinical trial with the new drug Atiprimod for patients with relapsed/refractory myeloma |
|
|
|
|
Dr. McGuirk reported on the first 70 patients enrolled in the AMD-3100 compassionate use program for poor stem cell mobilizers in need of stem cell harvest prior to autologous stem cell transplantation (SCT) |
|
Transplantation
|
|
|
|
Dr. Vij presented the results of a trial using GCSF alone in successful mobilization of stem cells |
|
Molecular Biology and Genetics, Other Research
|
|
|
Dr. Van Ness presented his current work with the IMF Bank On A Cure program’s genetic data along with information about current and future research being conducted by the Bank On A Cure Team |
|
|
|
|
Dr. Sonneveld studied single nucleotide polymorphisms (SNPs) collected from patient tissue samples in a large, multi-center, randomized, single versus double autologous transplant clinical trial |
|
|
|
|
|
Dr. Ludwig presented an analysis of clinical features and outcomes in 259 myeloma patients younger than 40 years versus 8,296 patients older than 40 years |
|
|
|
|
Dr. Fonseca’s presentation on the genetic abnormalities of patients diagnosed with MGUS or smoldering disease identifies those aberrations that can be seen prior to a myeloma diagnosis |
|
|
|
|
|
Dr. Vij's presentation dealt with markers of immune function and immune modulation after the use of Velcade in the peri-transplant setting (treatment with Velcade before and after transplant) |
|
|
|
|
|
Dr. Vij’s presentation concerned the effect of Velcade on markers of bone resorption |
|
|
|
|
|
Dr. Kumar’s presentation concerned the use of the free light chain (FLC) assay to assess disease and response to therapy, particularly in oligosecretory and non-secretory patients |
|
|
back
print
related articles